If Intarcia Therapeutics, Inc. can convince FDA to convene an advisory committee to assess its new drug application for ITCA 650 (exenatide implant) for treatment of type 2 diabetes, the Center for Drug Evaluation and Research wants the panel to consider deficiencies with the device component among other issues.
Last month, FDA chief scientist Namandjé Bumpus gave Intarcia the opportunity to request a public hearing before FDA’s Endocrinologic and...





